To characterize maternal and infant outcomes for pregnant women who received live H1N1 influenza vaccine and had no reported adverse events.
RESULTS:
The Vaccine Adverse Event Reporting System received 113 reports stating receipt of live H1N1 vaccine during pregnancy with no adverse events reported. We obtained follow-up maternal records on 95 of the 113 (84%) live H1N1 reports (40.2% were vaccinated in the first trimester) and found: 87 live births (two twin pregnancies) and no maternal deaths occurred. Number and rates of pregnancy-specific adverse events included: 10 (10.5%, 5.8-18.3) spontaneous abortions; four (4.7%, 1.8-11.4) preterm deliveries at 35-36 weeks of gestation; three (3.4%, 1.2-9.7) infants had one or more major birth defects noted at birth: one cleft palate, one cleft lip, and one microtia (underdeveloped or absent external ear). Seven neonates and infants were hospitalized for medically important conditions. One infant death occurred in a 2.5-month-old boy as a result of pertussis.
CONCLUSION:
Rates of spontaneous abortion, preterm birth, and major birth defects in pregnant women who received live H1N1 vaccine were similar to or lower than published background rates. No concerning patterns of medical conditions in infants were identified. as inactivated, split-virus or subunit vaccines for injection (inactivated H1N1) and as live, attenuated vaccine (live H1N1) for intranasal administration. 2 Consistent with seasonal influenza vaccine recommendations, pregnant women were given high priority to receive inactivated H1N1 vaccination; live H1N1 vaccine was not recommended for pregnant women. 3, 4 Nevertheless, some women did receive live H1N1 vaccine inadvertently during pregnancy, particularly during early pregnancy. Monitoring adverse events after 2009 H1N1 vaccine administration in pregnant women was a priority for the Centers for Disease Control and Prevention and the U.S. Food and Drug Administration. During October 2009 through June 2010, the Vaccine Adverse Event Reporting System received reports regarding pregnant women who had received 2009 H1N1 vaccines. Review of adverse events after the H1N1-inactivated vaccines revealed no safety concerns. 5 The Vaccine Adverse Event Reporting System also received reports for women who received live H1N1 during pregnancy without any associated adverse event, most likely motivated by maternal exposure to the live vaccine, which is not recommended. Using these reports as a convenience sample, we examined maternal and infant outcomes among pregnant women who received the live H1N1 vaccine during the 2009 pandemic and were reported to the Vaccine Adverse Event Reporting System without any documented adverse event at the time of the report.
MATERIAL AND METHODS
The Vaccine Adverse Event Reporting System, coadministered by the Centers for Disease Control and Prevention and the U.S. Food and Drug Administration, is the U.S. national spontaneous reporting system used to monitor vaccine safety after licensure. 6 The Vaccine Adverse Event Reporting System form collects information about the vaccine, adverse event, and characteristics of the vaccinee. Medication errors (eg, administration of an incorrect vaccine) may also be reported with or without reporting an associated adverse event. 6 Medical records are routinely obtained for serious adverse events or for prespecified conditions; during the 2009 H1N1 pandemic, medical records were requested for all reports indicating the vaccinee was pregnant at the time of receipt of the 2009 H1N1 vaccine and all reports concerning infants born to mothers who received 2009 H1N1 vaccines during pregnancy. 5 For women who received live attenuated influenza vaccines during pregnancy, we reviewed medical records to determine the pregnancy and infant outcomes through age 6 months.
Because the Vaccine Adverse Event Reporting System is a spontaneous reporting system, anyone at any time after vaccination can report to the Vaccine Adverse Event Reporting System. Women who experience adverse pregnancy outcomes may be more likely to recall having received a vaccine while pregnant and report both the exposure to a live vaccine and the adverse pregnancy outcome. These same women may not have reported receipt of live vaccine had they not experienced an adverse pregnancy outcome. We used the Vaccine Adverse Event Reporting System to identify a sample of pregnant women for whom the only documented reason for the report was inadvertent receipt of live H1N1 vaccine and no associated adverse event reported; we limited our primary analysis to these reports. We also collected follow-up information for initial reports that described an adverse event not related to pregnancy or infant outcomes such as injection site pain.
The Vaccine Adverse Event Reporting System is a routine surveillance program and is not subject to institutional review board review and informed consent requirements.
We abstracted demographic and health information data from the Vaccine Adverse Event Reporting System reports and medical records. For pregnancy or neonatal outcomes not available at the time of the initial report, we collected prenatal records, delivery reports, postpartum visits, and pediatric medical records for any outpatient visits, any hospitalizations up to 6 months after birth, or both. Physicians with pediatric and obstetric expertise reviewed reports and medical records. Gestational age at the time of vaccination was calculated based on the following: 1) clinical determination by the health care provider; 2) the earliest ultrasonographic assessment (if the former was not available); or 3) the last menstrual period, estimated delivery date, or estimated date of conception (if the first two options were not available). We defined trimesters by gestational age as follows: first (0-13 weeks of gestation), second (14-27 weeks of gestation), and third (28 weeks of gestation or greater). 7 We defined pregnancy outcomes as follows: spontaneous abortion as a fetal death occurring less than 20 weeks of gestation, stillbirth as a fetal death occurring 20 weeks of gestation or greater, and preterm birth occurring less than 37 weeks of gestation. Diagnosis for these and other pregnancy outcomes (ie, preeclampsia, eclampsia, small for gestational age) were accepted based on diagnosis as provided on the Vaccine Adverse Event Reporting System form or medical record. 7 We considered the neonatal period to be birth through 28 days of life. Major birth defects were assessed by pediatricians specializing in birth defects using recognized guidelines for their definition.
We also described hospitalizations in vaccinated women or their exposed infants for reasons other than routine delivery.
We calculated the rate of spontaneous abortions as the number of documented spontaneous abortions divided by the total number of pregnant women with known final outcome (live birth or fetal demise). The rate for preterm births or major birth defects was calculated using total number of live births as the denominator. We completed a sensitivity analysis to assess whether rates of pregnancy-specific adverse outcomes were altered when we included initial reports that described an adverse event that was not pregnancy-specific. We used SAS 9.2 for analyses.
RESULTS
From October 1, 2009, through June 30, 2010, the Vaccine Adverse Event Reporting System received 122 reports after live H1N1 vaccine given to pregnant women. Of these, 113 reported no adverse event in the initial report and were included in our primary analysis. An additional three reports that contained a nonpregnancy-specific adverse event were included in the sensitivity analysis (n5116). Six reports were excluded from both the primary and the sensitivity analysis because a pregnancy-specific adverse event was reported in the initial Vaccine Adverse Event Reporting System report ( (Table 1) .
We had sufficient information, primarily from delivery medical records, to assess pregnancy outcomes for 95 (84%) of 113 reports. No maternal deaths, stillbirths, elective terminations, or ectopic pregnancies were identified. Among the 95 reports, there were 84 singleton pregnancies resulting in 84 live births and there were two twin pregnancies resulting in three live births (one twin was a fetal demise [fetus papyraceous] at 12 weeks of gestation). The total number of live births, from singleton (84) and twin (two) pregnancies, was 87. Twenty-one (24.4%) of 86 deliveries were by cesarean. There were 10 spontaneous abortions (including the twin fetal demise) (10 of 95, 10.5%, 95% confidence interval [CI] 5.8-18.3). Nine of the 10 spontaneous abortion reports had information on gestational age at the time of the event: five reports stated the event occurred less than 12 weeks of gestation and four were between 12 and 15 weeks of gestation. The interval from vaccination to onset of symptoms of the spontaneous abortion (onset interval) was known for seven of 10. In two reports, the onset interval was less than 7 days and in five, the interval was between 26 and 54 days. One spontaneous abortion at 6 weeks of gestation was found to have trisomy 16 after chromosomal analysis. There were four preterm births (4.7%, 95% CI 1.8-11.4), three at 35 and one at 36 weeks of gestation. Three were indicated for medical reasons and one was spontaneous. All four women who experienced preterm delivery had at least one risk factor including preeclampsia, gestational hypertension, gestational diabetes, noninsulindependent diabetes mellitus, previous preterm births, and oligohydramnios. 9 One of the preterm infants was also small for gestational age. No women were hospitalized for reasons other than routine delivery. Three infants (3.4%, 95% CI 1.2-9.7) had one major birth defect each: one each of cleft palate, cleft lip, and microtia (underdeveloped or absent external ear) ( Table 2) .
The median maternal and gestational age at vaccination for the 95 women with, and the 18 women without, follow-up information was similar (data not shown).
Medical information about the infants born to women who received live H1N1 vaccine during pregnancy and had no adverse event was available for 79 (91.9%) of 86 women at the time of delivery; 58 (67.7%) infants had at least one medical record available for review during the 6-month follow-up. Five infants had temporary serious conditions in the neonatal period, which required prolonged hospitalization or rehospitalization (Table 3) . Most conditions present during the neonatal period were self-limited and included jaundice in 21 infants and one case each of macrosomia and abnormal heart rate at birth.
Although there were no deaths in the neonatal period, one male infant died at age 2.5 months as Data are median (range), n/N (%), or n (%, 95% confidence interval). * Gestational age unknown for six reports. † Other includes Mediterranean, Native American, and Asian. ‡ Of women with sufficient information to assess outcomes: other pregnancy outcomes include 13 reports of: premature rupture of membranes (four); pregnancy-induced hypertension (two); and one case each of chorioamnionitis and pyrexia, polyhydramnios, gestational diabetes, diabetes, urinary tract infection and pyrexia, postpartum hemorrhage secondary to lower uterine segment atony, postpartum endometritis, and pyrexia. § Includes two infants from one twin pregnancy. k Sixty-seven women vaccinated before 20 wk of gestation with final outcome data available; 10 spontaneous abortions include a fetal demise (fetus papyraceous) from a twin pregnancy in which the other fetus was born alive. ¶ One preterm birth also had preeclampsia. # Vaccinated at 35 wk of gestation.
a result of laboratory-confirmed pertussis. In addition, a 4-month-old male infant was hospitalized for 1 day with a diagnosis of respiratory syncytial virus bronchiolitis and acute otitis media. No other infants were hospitalized after the neonatal period. The five most common conditions diagnosed during pediatric outpatient visits were mild and self-limited and included: upper respiratory infection (15) , dermatitis (seven), gastroesophageal reflux disease (five), conjunctivitis, and obstruction of the nasolacrimal duct (three each).
The sensitivity analysis included the 116 reports (113 plus three reports with a nonpregnancy-specific adverse event reported); follow-up medical records were available for these three reports. Including these three records, the rates of spontaneous abortion, premature delivery, and major birth defects were 10.2% (5.6-17.8%; 10 of 98), 4.5% (1.8-10.9%; four of 89), and 3.3% (1.1-9.3%; three of 90), respectively.
DISCUSSION
We assessed pregnancy outcomes in women who received 2009 live H1N1 vaccine during pregnancy and were reported to the Vaccine Adverse Event Reporting System without an associated adverse event at the time of report. Our review did suggest that receipt of live attenuated 2009 pandemic influenza vaccine during pregnancy was not associated with increased risk for adverse health outcomes in pregnant women or their exposed infants. Rates of spontaneous abortion, preterm birth, and overall birth defects in women exposed to live H1N1 vaccine during pregnancy were similar to or lower than published background rates. 10 These rates did not differ when the additional three nonpregnancy-specific adverse events were included in the sensitivity analysis. In addition, clinical review of records of pregnant women and their infants up to 6 months of age did not identify any concerning patterns of medical conditions. Not shown in this table were three neonates born to mothers whose initial reports described an adverse event not related to a pregnancyspecific outcome. The adverse events were a report of dizziness, Bell's palsy, and neonatal jaundice. The neonate born in the maternal report of dizziness required hospitalization in the neonatal intensive care unit to rule out sepsis as a result of a vesicular rash also noted in the mother at the time of delivery. Laboratory tests and cultures in the neonates were negative, and the neonate and mother were discharged in good condition. The woman with Bell's palsy had an otherwise normal pregnancy and delivered a healthy full-term neonate. The neonate with mild neonatal jaundice had an uneventful clinical course. * Preterm birth at 36 weeks of gestation.
The spontaneous abortion rate of 10.5% among pregnant women who received 2009 live H1N1 vaccines is comparable to background rates of spontaneous abortion, which can vary from 10.4% in women aged younger than 25 years to 22.4% in women aged 34 years or older. 10 The available evidence has not shown an association between spontaneous abortion and trivalent inactivated influenza vaccine, although few studies have assessed this association. A casecontrol study of trivalent inactivated influenza vaccine and early pregnancy loss in the U.S. and cohort studies of 2009 H1N1 inactivated influenza vaccines in Europe did not identify an increased risk for spontaneous abortion or stillbirth after vaccination with either vaccine. [11] [12] [13] [14] The rate of preterm birth among pregnant women who received 2009 live H1N1 vaccines in this study (4.7%) is below observed background rates of 10.4-11.5% in the general population of pregnant women in the United States. 10, 13 Similarly, the proportion of small-for-gestational-age newborns (1.1%) was below the background rate for this condition (8-16%) . 15 Although these data do not suggest an association between 2009 live H1N1 vaccines and preterm birth or small for gestational age, it is not clear how to interpret our finding of lower rates compared with the U.S. population. It is possible the pregnant women in this study were a select population that would be expected to have a lower rate of preterm birth. For example, only 6.2% were African American, and the women were receiving either prenatal or primary care. 9, 16 However, because in our study 19% of reports represented adolescent pregnancies (15-19 years) , in contrast to 7% in the general population, and adolescents are at higher risk for preterm births, 17 we might have expected a higher rate of preterm births. Women receiving 2009 live H1N1 may have been healthier than the general population because live H1N1 was not recommended for persons with certain chronic conditions (eg, diabetes) 3 that may be associated with preterm birth. 7 Some studies have found an association between inactivated influenza vaccine and lower risk for preterm birth and small for gestational age possibly as a result of prevention of maternal influenza. [18] [19] [20] [21] A similar association between live attenuated influenza vaccine and these pregnancy outcomes is plausible but has not been studied.
The overall rate of major birth defects after live H1N1 vaccine identified in this study was 3.4%, which is similar to the overall background rate of 3%. 22 The small number of major birth defects observed does not allow us to make any conclusions about an association of live H1N1 vaccines and birth defects; however, it is reassuring that no increase in birth defects was observed. Many of the temporary serious conditions found among some infants were medical conditions often encountered in pediatric practice (eg, urinary tract infection, upper respiratory infection, respiratory distress), which may require hospitalization. 23 Reporting exposure to live H1N1 vaccine during pregnancy before knowledge of the pregnancy outcome reduces reporting bias and permits estimation of the risk of certain pregnancy outcomes. 24, 25 Traditionally spontaneous reporting systems like the Vaccine Adverse Event Reporting System are not able to yield reliable information about incidence of pregnancy outcomes in exposed women for two main reasons: reporting bias and lack of denominator data. 6 Our study provided a denominator by including pregnant women before adverse events were recognized, when the only motivating factor to report to the Vaccine Adverse Event Reporting System was exposure to the live vaccine, most likely inadvertently. We found a sizable number of reports, which only reported exposure to live H1N1 vaccine during pregnancy. We were able to prospectively assess maternal and infant outcomes in most of the women vaccinated during pregnancy through comprehensive medical record review. This approach allowed us to directly calculate rates for certain outcomes of interest with less reporting bias. It also minimized underreporting; relying on spontaneous reporting system surveillance alone, we would have only identified one spontaneous abortion report after live H1N1 vaccine; however, through active surveillance by obtaining medical records, we were able to identify 10 cases of spontaneous abortion after exposure to live vaccine. Our primary analysis excluded reports of any adverse event, including nonpregnancy-specific adverse events, and likely resulted in more conservative rate calculations because the three reports that included a nonpregnancy-specific adverse event did not result in an adverse pregnancy outcome. If, however, our review revealed that these three pregnancies resulted in an adverse pregnancy outcome, our primary results could have been biased. The sensitivity analysis demonstrated that inclusion of these reports did not change our results.
There are some limitations that should be noted. First, our sample size was small, and this limits precise estimation of risks for the main outcomes of interest. Pregnant women who received live H1N1 vaccines and whose health care providers reported to the Vaccine Adverse Event Reporting System may not be representative of the general population of pregnant women or pregnant women who received the live H1N1 vaccine in the United States.
Live vaccines administered to a pregnant woman pose real 26 (eg, smallpox vaccine) and theoretical risks to the fetus 27 ; therefore, live attenuated virus and live bacterial vaccines generally are contraindicated during pregnancy. 28 As a result of the mechanism of action of live H1N1 vaccines, risk to the fetus is unlikely. Live attenuated influenza vaccines are made from attenuated viruses that are able to replicate efficiently only at temperatures present in the nasal mucosa where the vaccine is administered. Rhinorrhea is the most common symptom after live attenuated influenza vaccines which may be related to local viral replication. 28 Transplacental passage of live influenza vaccine virus has not been documented.
Although our study was a convenience sample from a passive reporting database and was not adequately powered to detect rare events with precision, it is reassuring that no concerning pattern of adverse events was observed in pregnant women or their infants who received the live H1N1 vaccines. However, those instances when live influenza vaccine was administered to a woman known to be pregnant emphasizes the need to provide continued education to vaccine administrators to ensure they are familiar with influenza vaccine recommendations. 29, 30 This method of enhanced surveillance may be useful to complement traditional pregnancy registries when a large number of pregnant women may be exposed to a vaccine such as during an epidemic, and may also be useful in situations when inadvertent administration of a vaccine not recommended during pregnancy is more likely to occur such as with adolescent vaccines to evaluate safety and provide additional evidence to inform policy.
